Adaptive Biotechnologies
ADPT
298 hedge funds and large institutions have $2.11B invested in Adaptive Biotechnologies in 2026 Q1 according to their latest regulatory filings, with 57 funds opening new positions, 102 increasing their positions, 95 reducing their positions, and 38 closing their positions.
592% more call options, than puts
Call options by funds: $1.14M | Put options by funds: $165K
50% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 38
5% more funds holding
Funds holding: 283 → 298 (+15)
7% more repeat investments, than reductions
Existing positions increased: 102 | Existing positions reduced: 95
0.23% more ownership
Funds ownership: 98.44% → 98.67% (+0.23%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
14% less capital invested
Capital invested by funds: $2.44B → $2.11B (-$332M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Asset Management
Paris,
France
|
+$42.8M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$27M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
+$21.9M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$21.4M |
| 5 |
CFM
Capricorn Fund Managers
London,
United Kingdom
|
+$20.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$44.9M |
| 2 |
Jennison Associates
New York
|
-$30.6M |
| 3 |
PTPFOECYE
PBU - The Pension Fund of Early Childhood & Youth Educators
Copenhagen,
|
-$20.3M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$19M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$16.1M |
ADPT Hedge Fund Activity: Q1 2026 in Review
298 of the 8,180 institutional investors tracked by Wall St. Rank reported a position in Adaptive Biotechnologies (ADPT) for Q1 2026, worth a combined $2.11B — down 14% from $2.44B a quarter earlier.
Buyers outnumbered sellers: 57 funds opened new ADPT positions and 38 closed out — a net gain of 19 holders — while 102 added to existing stakes and 95 trimmed.
The largest buyer was BNP Paribas Asset Management, opening a new position worth an estimated $42.8M. The largest seller was T. Rowe Price Associates, cutting an estimated $44.9M.
- 298 institutional investors held Adaptive Biotechnologies (ADPT) as of Q1 2026, up from 283 in Q4 2025.
- Funds reported $2.11B of Adaptive Biotechnologies stock for Q1 2026, down 14% quarter-over-quarter.
- 57 funds opened new Adaptive Biotechnologies positions in Q1 2026 and 38 closed out, a net change of +19 holders.
- The largest Adaptive Biotechnologies buyer in Q1 2026 was BNP Paribas Asset Management, an estimated $42.8M added.
- The largest Adaptive Biotechnologies seller in Q1 2026 was T. Rowe Price Associates, an estimated $44.9M sold.
Based on aggregated 13F filings for Q1 2026.